We are pleased to provide the recap of the 14th annual PODD: Partnership Opportunities in Drug Delivery conference, which took place on October 27-28, 2024. For those who were in attendance, enjoy the photos and a snap shot of a number of highlights and to those who were not able to join us, we are pleased to keep you in the loop.
Click this text to access the full recap
Attendees heard from senior drug delivery executives from pharmaceutical, biotech, medical device, and across all areas of drug delivery to develop more effective therapies for patients, improve the patient experience of taking medicine and extend the life cycle of the medicine through collaboration and innovation.
Day One began with the Annual Keynote Fireside Discussion where Dr Robert Langer was joined by Dr Richard Tillyer, Global Head of Discovery, Product Development and Supply at Johnson & Johnson about nanoparticle delivery of cell therapies and genetic engineering for various indications and oral delivery of macromolecules and GLP-1s. Genentech’s Aly Jackson spoke about market trends, drug approval highlights, drug delivery partnerships and highlighted therapeutic areas in her Industry Overview on the 2024 Drug Delivery Landscape.
Zeitgeist presenter, Dr Anand Subramony, Senior Vice President, Devices & Delivery Solutions, Novo Nordisk, discussed the Re-Emergence of Drug Delivery Facilitated by the Disruption Effects of GLP-1 Drugs and Nucleic Acid Modalities.
Day Two began with Gene Delivery Keynote, Dr Laura Sepp- Lorenzino, PhD, CSO, Intellia Therapeutics, who presented on The Evolution of Delivery Approaches for In Vivo Gene Editing to Achieve Meaningful Clinical Impact.
Across the two days, there were panel discussions on:
• Ex-Liver Delivery of RNA/DNA
• Payer Perspectives on Drug Delivery
• The Realities of Developing Self Administration of Subcutaneous Therapeutics
• AI Approaches to Deliver Cell & Gene Therapy
• New Approaches to Achieve Targeted CNS Delivery without Increasing Toxicity
• Advances in Pulmonary Delivery of Biologics
• Translating Digital Health from the Clinic to Commercialization
• Vaccine Delivery Innovations
• Improving Bioavailability and Stability Through Excipient Innovation
• Balancing Between Concentration and Volume for Patient-Centric Biologics
• Designing and Developing Drug Delivery for LMICs
• Achieving Oral Delivery of Peptides
• Developing Closed Loop Systems
• Sustained Release Innovations to Reduce Patient Burden
• Focused Ultrasound Delivery
• Biomaterial Implants to Reduce Patient Burden
Across multiple tracks, PODD speakers presented case studies and thought-provoking presentations on:
• Injectable Formulations & Technologies
• Novel Devices: Self-Injectables, Wearables & Connected Devices
• Oral, Mucosal, Transdermal & Other Non-Injectable Technologies
• Cell & Gene Delivery
• Excipient Innovation
• Novel Device Technologies
• Novel Injectable and Non-Injectable Technologies
• Cell, Gene & Novel Biologics Deliver
• Self-Injection Devices, Syringes, Primary Container & Packaging Solutions
We had a record-breaking attendance with over 950 delegates generating a wonderful energy in the sessions, the partnering and exhibit hall. Many thanks to all who participated. Enjoy this special summary and we also give you information through the PODD website, recommended media and upcoming events. A big thank you to everyone who participated in this year’s PODD.
